The decision to pursue IVF is deeply personal, and for many patients, another question naturally follows: Can you pick gender with IVF? Some individuals ask for medical reasons, such as preventing inherited sex-linked conditions, while others consider it as part of a thoughtful family planning decision. Both motivations deserve a clear and medically accurate explanation.
In the United States, the answer is yes. Gender selection through IVF is possible when the treatment includes preimplantation genetic testing (PGT-A), a form of chromosomal screening performed on embryos during the IVF process.
Let’s explain how sex selection works, who it may be appropriate for, and what patients should realistically expect.
Can You Pick Gender With IVF?
Yes, it is possible to select the biological sex of an embryo through IVF when the process includes preimplantation genetic testing for aneuploidy (PGT-A). This test analyzes the chromosomes of embryos created through IVF and determines whether an embryo has XX chromosomes (female) or XY chromosomes (male).
It is important to distinguish between biological sex, which refers to chromosomes, and gender identity, which relates to personal identity and social experience. PGT-A determines chromosomal sex only.
Sex selection through IVF is legal in the United States, although regulations vary internationally. The process occurs as part of a standard IVF cycle and is not a separate fertility treatment.
How Does Sex Selection Through IVF Work?
Sex selection during IVF occurs through preimplantation genetic testing for aneuploidy (PGT-A), which evaluates embryos for chromosomal health. This testing is performed when embryos reach the blastocyst stage, typically on Day 5 or Day 6 after fertilization.
The process involves several steps:
- Ovarian stimulation and egg retrieval: Fertility medications stimulate the ovaries to produce multiple eggs. These eggs are collected during a short outpatient procedure.
- Fertilization and embryo development: The eggs are fertilized with sperm in an embryology laboratory. Embryos grow in controlled incubators until they reach the blastocyst stage.
- Trophectoderm biopsy: At the blastocyst stage, a small number of cells are carefully removed from the outer layer of the embryo. This biopsy does not damage the portion of the embryo that will become the fetus.
- Chromosomal analysis: The biopsied cells are sent to a specialized genetics laboratory. Chromosomal testing identifies whether the embryo has XX or XY chromosomes and evaluates overall chromosomal health.
- Results review: The fertility specialist reviews the genetic results with the patient. These results show both the chromosomal status and the biological sex of each embryo.
- Frozen embryo transfer: A selected embryo is transferred to the uterus during a frozen embryo transfer cycle.
When performed at the blastocyst stage by an experienced laboratory, PGT-A determines biological sex with nearly 100 percent accuracy. Importantly, sex identification is only one part of the test. The primary purpose of PGT-A is to identify embryos with the healthiest chromosomal profile.
Who Is Sex Selection Recommended For?
Sex selection through IVF may be considered for medical reasons or personal family planning goals.
Medical Indications
In some cases, selecting the biological sex of an embryo helps prevent serious inherited conditions. These include X-linked genetic disorders, where one sex carries a higher risk of disease. Examples include:
- Hemophilia
- Duchenne muscular dystrophy
- Fragile X syndrome
Sex selection may also be recommended for patients with X-linked dominant conditions or chromosomal structural abnormalities that affect one biological sex more significantly.
Elective Indications (Family Balancing)
Some patients pursue sex selection for family balancing, meaning they already have children of one biological sex and hope to have a child of the other.
Elective sex selection is also requested by single parents or LGBTQ+ individuals planning biological parenthood with a preference for a specific sex. Although elective sex selection is legal in the United States, policies vary by fertility clinic.
What Does the ASRM Say About Sex Selection?
The American Society for Reproductive Medicine (ASRM) provides ethical guidance on the use of reproductive technologies, including sex selection.
According to the ASRM Ethics Committee:
- Using PGT to prevent serious sex-linked genetic diseases is considered ethically acceptable.
- Using PGT for elective sex selection without a medical indication requires careful ethical consideration.
The ASRM has not issued a universal prohibition on elective sex selection but recommends that clinics maintain transparent policies and ensure patients receive appropriate counseling before proceeding.
Because clinic policies vary, patients should consult with a board-certified reproductive endocrinologist to determine whether sex selection is available and appropriate for their circumstances.
Important Considerations Before Pursuing Sex Selection
Before deciding to pursue sex selection through IVF, patients should understand several practical factors.
- Embryo availability: Sex selection depends on the embryos created during the IVF cycle. There is no guarantee that embryos of the desired biological sex will be available. Age, ovarian reserve, egg quality, and sperm health all influence embryo outcomes.
- Embryo selection decisions: In some cycles, all chromosomally normal embryos may be the same biological sex. Patients should discuss in advance how they would proceed in this situation.
- Emotional preparation: The IVF process already requires emotional commitment. Waiting for genetic testing results and embryo selection decisions can add additional stress for some patients.
- Clinic policies: Not all fertility clinics offer elective sex selection. Patients should confirm the clinic’s policy before beginning treatment.
What Does Sex Selection Cost?
Adding PGT-A testing for sex selection typically increases the cost of an IVF cycle by approximately $3,000 to $5,000 in the United States.
Total IVF costs vary by clinic, geographic location, and individual treatment protocol. Because elective sex selection is usually not considered medically necessary, insurance coverage is uncommon. Financial counseling during a fertility consultation can help patients understand available options.
Conclusion
Sex selection through IVF is a scientifically precise process made possible through advanced genetic testing. In the United States, it is legally available and may be pursued for both medical and family-planning purposes. Because embryo health remains the primary focus of treatment, sex identification occurs as part of comprehensive chromosomal screening.
Every patient’s fertility journey is unique. Understanding eligibility, clinic policies, and individual treatment considerations requires consultation with an experienced specialist.
Begin Your Fertility Consultation With White Glove Fertility
At White Glove Fertility, IVF treatment plans are designed around each patient’s fertility history, diagnostic results, and family-building goals. Care is led by Dr. Jonah Bardos, a board-certified reproductive endocrinologist with expertise in reproductive genetics and preimplantation genetic testing.
To schedule a consultation, call (305) 735-8000 or visit 1140 Kane Concourse, 5th Floor, Bay Harbor Islands, FL 33154.
FAQs
Is sex selection through IVF legal in the United States?
Yes. Sex selection through IVF combined with preimplantation genetic testing is legal in the United States for both medical and elective purposes. However, individual fertility clinics may establish their own policies regarding whether elective sex selection is offered.
How accurate is sex selection through IVF?
When performed at the blastocyst stage using PGT-A, chromosomal testing can determine the biological sex of an embryo with nearly 100% accuracy. Accuracy depends on proper embryo biopsy techniques and testing performed by a certified genetics laboratory.
Does sex selection affect IVF success rates?
Sex selection itself does not reduce IVF success rates. Because PGT-A also identifies chromosomally normal embryos, the process may improve implantation outcomes and reduce miscarriage risk compared with transferring unscreened embryos.